Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant

Vaccine adjuvants from natural resources have been utilized for enhancing vaccine efficacy against infectious diseases. This study examined the potential use of catechins, polyphenolic materials derived from green tea, as adjuvants for subunit and inactivated vaccines. Previously, catechins have bee...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yucheol Cheong, Minjin Kim, Jina Ahn, Hana Oh, Jongkwan Lim, Wonil Chae, Seung Won Yang, Min Seok Kim, Ji Eun Yu, Sanguine Byun, Yo Han Jang, Baik Lin Seong
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	EGCG adjuvant IgG isotype switching influenza ADCC Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/4f49ccb7cfa84854a546face6860009a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f49ccb7cfa84854a546face6860009a
record_format	dspace
spelling	oai:doaj.org-article:4f49ccb7cfa84854a546face6860009a2021-11-12T04:46:03ZEpigallocatechin-3-Gallate as a Novel Vaccine Adjuvant1664-322410.3389/fimmu.2021.769088https://doaj.org/article/4f49ccb7cfa84854a546face6860009a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.769088/fullhttps://doaj.org/toc/1664-3224Vaccine adjuvants from natural resources have been utilized for enhancing vaccine efficacy against infectious diseases. This study examined the potential use of catechins, polyphenolic materials derived from green tea, as adjuvants for subunit and inactivated vaccines. Previously, catechins have been documented to have irreversible virucidal function, with the possible applicability in the inactivated viral vaccine platform. In a mouse model, the coadministration of epigallocatechin-3-gallate (EGCG) with influenza hemagglutinin (HA) antigens induced high levels of neutralizing antibodies, comparable to that induced by alum, providing complete protection against the lethal challenge. Adjuvant effects were observed for all types of HA antigens, including recombinant full-length HA and HA1 globular domain, and egg-derived inactivated split influenza vaccines. The combination of alum and EGCG further increased neutralizing (NT) antibody titers with the corresponding hemagglutination inhibition (HI) titers, demonstrating a dose-sparing effect. Remarkably, EGCG induced immunoglobulin isotype switching from IgG1 to IgG2a (approximately >64–700 fold increase), exerting a more balanced TH1/TH2 response compared to alum. The upregulation of IgG2a correlated with significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) function (approximately 14 fold increase), providing a potent effector-mediated protection in addition to NT and HI. As the first report on a novel class of vaccine adjuvants with built-in virucidal activities, the results of this study will help improve the efficacy and safety of vaccines for pandemic preparedness.Yucheol CheongMinjin KimJina AhnHana OhJongkwan LimWonil ChaeSeung Won YangMin Seok KimJi Eun YuSanguine ByunYo Han JangYo Han JangBaik Lin SeongBaik Lin SeongFrontiers Media S.A.articleEGCGadjuvantIgG isotype switchinginfluenzaADCCImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	EGCG adjuvant IgG isotype switching influenza ADCC Immunologic diseases. Allergy RC581-607
spellingShingle	EGCG adjuvant IgG isotype switching influenza ADCC Immunologic diseases. Allergy RC581-607 Yucheol Cheong Minjin Kim Jina Ahn Hana Oh Jongkwan Lim Wonil Chae Seung Won Yang Min Seok Kim Ji Eun Yu Sanguine Byun Yo Han Jang Yo Han Jang Baik Lin Seong Baik Lin Seong Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
description	Vaccine adjuvants from natural resources have been utilized for enhancing vaccine efficacy against infectious diseases. This study examined the potential use of catechins, polyphenolic materials derived from green tea, as adjuvants for subunit and inactivated vaccines. Previously, catechins have been documented to have irreversible virucidal function, with the possible applicability in the inactivated viral vaccine platform. In a mouse model, the coadministration of epigallocatechin-3-gallate (EGCG) with influenza hemagglutinin (HA) antigens induced high levels of neutralizing antibodies, comparable to that induced by alum, providing complete protection against the lethal challenge. Adjuvant effects were observed for all types of HA antigens, including recombinant full-length HA and HA1 globular domain, and egg-derived inactivated split influenza vaccines. The combination of alum and EGCG further increased neutralizing (NT) antibody titers with the corresponding hemagglutination inhibition (HI) titers, demonstrating a dose-sparing effect. Remarkably, EGCG induced immunoglobulin isotype switching from IgG1 to IgG2a (approximately >64–700 fold increase), exerting a more balanced TH1/TH2 response compared to alum. The upregulation of IgG2a correlated with significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) function (approximately 14 fold increase), providing a potent effector-mediated protection in addition to NT and HI. As the first report on a novel class of vaccine adjuvants with built-in virucidal activities, the results of this study will help improve the efficacy and safety of vaccines for pandemic preparedness.
format	article
author	Yucheol Cheong Minjin Kim Jina Ahn Hana Oh Jongkwan Lim Wonil Chae Seung Won Yang Min Seok Kim Ji Eun Yu Sanguine Byun Yo Han Jang Yo Han Jang Baik Lin Seong Baik Lin Seong
author_facet	Yucheol Cheong Minjin Kim Jina Ahn Hana Oh Jongkwan Lim Wonil Chae Seung Won Yang Min Seok Kim Ji Eun Yu Sanguine Byun Yo Han Jang Yo Han Jang Baik Lin Seong Baik Lin Seong
author_sort	Yucheol Cheong
title	Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
title_short	Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
title_full	Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
title_fullStr	Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
title_full_unstemmed	Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
title_sort	epigallocatechin-3-gallate as a novel vaccine adjuvant
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/4f49ccb7cfa84854a546face6860009a
work_keys_str_mv	AT yucheolcheong epigallocatechin3gallateasanovelvaccineadjuvant AT minjinkim epigallocatechin3gallateasanovelvaccineadjuvant AT jinaahn epigallocatechin3gallateasanovelvaccineadjuvant AT hanaoh epigallocatechin3gallateasanovelvaccineadjuvant AT jongkwanlim epigallocatechin3gallateasanovelvaccineadjuvant AT wonilchae epigallocatechin3gallateasanovelvaccineadjuvant AT seungwonyang epigallocatechin3gallateasanovelvaccineadjuvant AT minseokkim epigallocatechin3gallateasanovelvaccineadjuvant AT jieunyu epigallocatechin3gallateasanovelvaccineadjuvant AT sanguinebyun epigallocatechin3gallateasanovelvaccineadjuvant AT yohanjang epigallocatechin3gallateasanovelvaccineadjuvant AT yohanjang epigallocatechin3gallateasanovelvaccineadjuvant AT baiklinseong epigallocatechin3gallateasanovelvaccineadjuvant AT baiklinseong epigallocatechin3gallateasanovelvaccineadjuvant
_version_	1718431228777988096

Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant

Ejemplares similares